Lab Corp and Atherotech Form Marketing Alliance

A marketing and distribution alliance relating to a new cholesterol test has been announced by Laboratory Corporation of America (LabCorp, Burlington, NC, USA) and Atherotech (Birmingham, AL, USA).

The agreement provides for the transfer of Atherotech's patented testing technology to LabCorp and, if certain conditions are met, LabCorp would then become the first clinical laboratory licensed to perform the assay for assessment of cardiovascular disease risk. The assay, called VAP (vertical auto profile), is an expanded cholesterol test designed to improve the identification of people at risk of heart disease by providing direct, detailed measurements of cholesterol subclasses that play important roles in the development of heart disease.

"We are pleased to offer the VAP Cholesterol Test as part of our broadly available menu of service offerings for cardiovascular disease,” said Myla Lai-Goldman, M.D., executive vice president, medical director, and chief scientific officer for LabCorp. "Many of our physician customers have been asking for this valuable test to help improve patient care.”

LabCorp is a leading US clinical laboratory, whose customers include doctors, hospitals, clinics, and other clinical laboratories. Atherotech is dedicated to improving the prevention, early diagnosis, and treatment of heart disease and other cardiovascular diseases.





Related Links:
LabCorp
Atherotech